Ingenia Therapeutics Goes Public on KOSDAQ

MT Newswires Live

Aug 18

Ingenia Therapeutics, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.

Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.

Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.

The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.

The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2660465414"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660465414\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660465414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 17:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660465414","market":"sh","top_or_hot":-1,"title":"Ingenia Therapeutics Goes Public on KOSDAQ","media":"MT Newswires Live","content":"<html><body><p> Ingenia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.</p><p>Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.</p><p>Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.</p><p>The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.</p><p>The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ingenia Therapeutics Goes Public on KOSDAQ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIngenia Therapeutics Goes Public on KOSDAQ\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-18 17:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ingenia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.</p><p>Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.</p><p>Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.</p><p>The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.</p><p>The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2660465414","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660465414","pubTimestamp":1787045589,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ingenia Therapeutics, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease  and IGT-532 for solid tumors","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","LENZ":"Therapeutics","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Ingenia Therapeutics 在 KOSDAQ 上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5},"content_text":"Ingenia Therapeutics, a clinical-stage biotechnology company, has gone public on South Korea's KOSDAQ market, according to a statement on Tuesday.Founded in Boston in 2018, the company uses two proprietary technologies designed to repair weakened blood vessels and clear out harmful proteins that drive disease.Its lead drug candidate, IGT-427, is being tested in late-stage trials for two serious eye conditions-age-related macular degeneration and diabetic macular edema.The program continues through a licensing deal with Merck, which acquired Ingenia's partner EyeBio in 2024.The IPO funds will also speed up development of other treatments, including IGT-303 for chronic kidney disease (currently in mid-stage patient trials) and IGT-532 for solid tumors","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}